In March, Cigna and its pharmacy benefit manager subsidiary Evernorth announced plans to limit spending increases on GLP-1 drugs at 15% per year. The goal is to expand access to the diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results